Ludwig Institut für Krebsforschung AG

Pilatus Biosciences announced FDA Orphan Drug Designation for PLT012, its leading molecule for treating liver and intrahepatic bile duct cancer. PLT012, a humanized anti-CD36 antibody, targets metabolic checkpoints to reprogram the tumor microenvironment, showing potential against multiple tumors. The designation supports Pilatus' commitment to innovative therapies for underserved cancer patients.

Swiss researchers developed a CAR-T cell therapy with on/off switches activated by approved drugs, aiming to improve safety and efficacy for solid tumor treatment.

Researchers at the Ludwig Institute developed NeoDisc, an AI-enabled computational pipeline integrating genomic, transcriptomic, and immunopeptidomics to predict neoantigens for personalized cancer vaccines, outperforming existing tools in clinical trials.

Ludwig Cancer Research scientists developed NeoDisc, a computational pipeline integrating molecular and genetic analyses of tumors and T cells, using AI to design personalized cancer vaccines. Published in *Nature Biotechnology*, NeoDisc identifies and prioritizes tumor-specific antigens, detects antigen presentation defects, and visualizes tumor heterogeneity, enhancing personalized immunotherapy efficacy.

Ludwig Cancer Research scientists developed NeoDisc, an AI-powered computational pipeline integrating molecular and genetic analyses to design personalized cancer vaccines, detailed in a Nature Biotechnology publication.